title: ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model.
abstract: In this study, we hypothesized that the mice immunized with the glycosylphosphatidylinositol (GPI) anchored 6-kDa early-secreted antigenic target (ESAT-6) DNA vaccine (ESAT-6-gpi) and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 might significantly enhance immune responses and antimelanoma efficacy. Our experimental results indicated that the anti-ESAT-6 antibody induced by the DNA vaccine ESAT-6-gpi bound ESAT-6 to the surface of tumour vaccine to activate a complement classical pathway and resulted in the B16F10 tumour cell lysis and apoptosis, which served as a potential trigger for breaking melanomatous immune tolerance to elicit an initiation of natural antimelanoma immunity. Our innovative approach of using the DNA vaccine ESAT-6-gpi priming and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 boosting induced strong antimelanoma immunity that inhibited melanomatous growth. These findings highlighted the DNA vaccine ESAT-6-gpi as an immune enhancer to augment the immune efficacy of the tumour vaccine B16F10-ESAT -6-gpi/IL-21 against melanoma in a mouse model.
authors.affiliation: Department of Pathogenic Biology and Immunology, Medical School, Southeast University, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: He
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: F
authors.initials: F
authors.lastname: Zhao
authors.forename: D
authors.initials: D
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Yang
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Dou
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D017261:Glycosylphosphatidylinositols / Q000008:administration & dosage*; D007114:Immunization; D007378:Interleukins / Q000276:immunology*; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D019444:Vaccines, DNA / Q000276:immunology*; D000098546:Interleukin-21
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D019496:Cancer Vaccines; C093276:ESAT-6 protein, Mycobacterium tuberculosis; D017261:Glycosylphosphatidylinositols; D007378:Interleukins; D019444:Vaccines, DNA; C081751:plasmanylinositol glycan; D000098546:Interleukin-21